Comparison · NCT00739674-sae
Losartan-Based Regimen Alone (L Group) vs Diet Management and Losartan-Based Regimen (DML Group): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Losartan-Based Regimen Alone (L Group) vs Diet Management and Losartan-Based Regimen (DML Group): serious adverse events. Trial comparisons, record NCT00739674-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00739674-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0245 | 0.0144 | 0.0414 | wilson | |
| Risk in group 2 | 0.0221 | 0.012 | 0.0402 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00241 | -0.0183 | 0.0221 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.11 | 0.491 | 2.51 | log | |
| Odds ratio, group 1 over group 2 | 1.11 | 0.483 | 2.56 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Losartan-Based Regimen Alone (L Group) than on Diet Management and Losartan-Based Regimen (DML Group) | 415 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Losartan-Based Regimen Alone (L Group) | Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure. | 13 | 531 | EG000 |
| Group 2 | Diet Management and Losartan-Based Regimen (DML Group) | Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management. | 10 | 453 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)
- NCT number
- NCT00739674
- Phases
- PHASE3
- Conditions
- Hypertension
- Interventions
- losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB]), Low Salt Diet
- Lead sponsor
- Organon and Co
- Results first posted
- 2010-08-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00739674?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00739674-sae